摘要
伴随着遗传药理学的发展,人们逐渐认识到基因多态性不能完全解释降压药物疗效的个体差异。在分子水平上,高血压药物相关代谢酶、受体、转运体都受到基因表达调控的影响,并在降压疗效差异中起着重要的作用。因此,从表观遗传学的角度研究遗传因素与降压药物之间的关系,将有助于更好地解释临床上药物反应产生的个体差异。本文综述总结了DNA甲基化、组蛋白修饰和microRNAs等表观遗传调控方式对高血压相关药物编码基因的影响。
With the development of pharma- cogenetics, people gradually realize that gene polymorphism cannot fully explain the antihy- pertensive drugs curative effect of individual differences. At the molecular level,many antihy- pertensive drugs related metabolic enzyme, re- ceptors,transporter are subject to the influence of the regulation of gene expression,and play an important role in differences of antihypertensive treatment. Therefore, from the perspective of epigenetics genetic factors and the relationship between the antihypertensive drugs, will help tobetter explain the clinical drug reaction from the individual differences. This review summarizes the DNA methylation, histone modification and microRNAs, apparent genetic control way for an- tihypertensive related drugs coding genetic effects.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2013年第3期351-355,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
中南大学中央高校基本科研业务费专项资金资助(2012zzts036)
国家重大新药创制专项(2012ZX09303014-001)
十二五国家科技支撑计划(SQ2012BAJY3779)
973前期研究专项(2011CB512001)
